[1]
Gomez, D.S.; Campos, E.V.; Azevedo, R.P.; Silva, J.M.; Ferreira, M.C.; Sanches-Giraud, C.; Silva Júnior, C.V.; Santos, S.R. Individualised vancomycin doses for pediatric burn patients to achieve PK/PD targets. Burns, 2013, 39(3), 445-450.
[2]
Pacifici, G.; Allegaert, K. Clinical pharmacokinetics of vancomycin in the neonate: A review. Clinics, 2012, 67(7), 831-837.
[3]
Marqués-Miñana, M.R.; Saadeddin, A.; Peris, J.E. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br. J. Clin. Pharmacol., 2010, 70(5), 713-720.
[4]
Pai, M.P.; Neely, M.; Rodvold, K.A.; Lodise, T.P. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv. Drug Deliv. Rev., 2014, 20(77), 50-57.
[5]
Marsot, A.; Boulamery, A.; Bruguerolle, B.; Simon, N. Vancomycin: A review of population pharmacokinetic analyses. Clin. Pharmacokinet., 2012, 51(1), 1-13.
[6]
Radigan, E.A.; Gilchrist, N.A.; Miller, M.A. Management of aminoglycosides in the intensive care unit. J. Intensive Care Med., 2010, 25(6), 327-342.
[7]
Yamamoto, M.; Kuzuya, T.; Baba, B.; Yamada, K.; Nabeshima, T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J. Clin. Pharm. Ther., 2009, 34(4), 473-483.
[8]
Hwang, D.; Chiu, N.C.; Chang, L.; Peng, C.C.; Huang, D.T.; Huang, F.Y.; Chi, H. Vancomycin dosing and target attainment in children. J. Microbiol. Immunol. Infect., 2015, 50(4), 494-499.
[9]
Santos, L.; Torriani, M.S.; Barros, E. Medicamentos na Prática da Farmácia Clínica, 1st ed; Artmed Editora: Porto Alegre, 2013.
[10]
Broome, L.; So, T.Y. An Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents. Int. J. Pediatr., 2011, 2011, 470364.
[11]
Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; Rybak, M.J.; Talan, D.A.; Chambers, H.F. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis., 2011, 52(3), e18-e55.
[12]
Alves, M.L.P.; Melo, G.A.N.; Yamada, S.S.; Nishiyama, P. Therapeutic monitoring of vancomycin. Acta Sci. Heal. Sci., 2012, 34(2), 199-204.
[13]
Rybak, M.J.; Lomaestro, B.M.; Rotschafer, J.C.; Moellering, R.C.; Craig, W.A.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis., 2009, 49(3), 325-327.
[14]
Touw, D.J.; Neef, C.; Thomson, A.H.; Vinks, A.A. Cost-effectiveness of therapeutic drug monitoring: A systematic review. Ther. Drug Monit., 2005, 27(1), 10-17.
[15]
Hoang, J.; Dersch-Mills, D.; Bresee, L.; Kraft, T.; Vanderkooi, O.G. Achieving therapeutic vancomycin levels in pediatric. Can. J. Hosp. Pharm., 2014, 67(6), 416-422.
[16]
Silva, D.C.B.; Seixas, G.T.F.; Araújo, O.R.; Arduini, R.G.; Carlesse, F.A.; Petrilli, A.S. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients. Braz. J. Infect. Dis., 2012, 16(4), 361-365.
[17]
Benner, K.W.; Worthington, M.A.; Kimberlin, D.W.; Hill, K.; Buckley, K.; Tofil, N.M. Correlation of vancomycin dosing to serum concentrations in pediatric patients: A retrospective database review. J. Pediatr. Pharmacol. Ther., 2009, 14(2), 86-93.
[18]
Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis., 2006, 42(Suppl. 1), S35-S39.
[19]
DiPiro, J.T.; Spruill, W.J.; Wade, W.E.; Blouin, R.A.; Pruemer, J.M. Concepts in clinical pharmacokinetics, 4th ed; American Society of Health-System Pharmacists: Bethesda, 2005.
[20]
Schwartz, G.J.; Muñoz, A.; Schneider, M.F.; Mak, R.H.; Kaskel, F.; Warady, B.A.; Furth, S.L. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol., 2009, 20(3), 629-637.
[21]
Gupta, A.; Biyani, M.; Khaira, A. Vancomycin nephrotoxicity: Myths and facts. Neth. J. Med., 2011, 69(9), 379-383.
[22]
James, C.W.; Gurk-Turner, C. Recommendations for monitoring serum vancomycin concentrations. Proc. Bayl. Univ. Med. Cent., 2011, 14(2), 189-190.
[23]
Dombroski, V.; Silva, M.M.G.; Silveira, M.E. Monitoramento terapêutico de vancomicina em uma unidade de terapia intensiva. Rev Médica UFPR, 2015, 2(2), 67-73.
[24]
Santos, A.B.; Duarte, A.; Saião, A.S. Vancomycin in clinical practice - a review. JBBR, 2011, 8(2), 321-327.
[25]
Van Hal, S.J.; Paterson, D.L.; Lodise, T.P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother., 2013, 57(2), 734-744.
[26]
Elyasi, S.; Khalili, H.; Hatamkhani, S.; Dashti-Khavidaki, S. Prevention of vancomycin induced nephrotoxicity: A review of preclinical data. Eur. J. Clin. Pharmacol., 2013, 69(4), 747-754.
[27]
Elyasi, S.; Khalili, H.; Dashti-Khavidaki, S.; Mohammadpour, A. Vancomycin-induced nephrotoxicity: Mechanism, incidence, risk factors and special populations. A literature review. Eur. J. Clin. Pharmacol., 2012, 68(9), 1243-1255.
[28]
Hazlewood, K.A.; Brouse, S.D.; Pitcher, W.D.; Hall, R.G. Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination? Am. J. Med., 2010, 123(2), 182.e1-182.e7.
[29]
Kim, D.I.; Im, M.S.; Choi, J.H.; Lee, J.; Choi, E.H.; Lee, H.J. Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean J. Pediatr., 2010, 53(12), 1000-1005.
[30]
Pea, F.; Porreca, L.; Baraldo, M.; Furlanut, M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J. Antimicrob. Chemother., 2000, 45(3), 329-335.
[31]
Higgins, C. Urea and the clinical value of measuring blood urea concentration. 2016. Article downloaded from acutecaretesting.org.
[32]
Moffett, B.S.; Kim, S.; Edwards, M. Vancomycin nephrotoxicity may be overstated. J. Pediatr., 2011, 158(5), 865-866.
[33]
Zanotto, M.B.; Wappler, P.R.; d’Azevedo, P.A.; Carneiro, M.; Rauber, J.M.; Valim, A.R.M. Avaliação dos níveis séricos de vancomicina em pacientes internados em um hospital de ensino da região central do Rio Grande do Sul - Brasil. Rev. Jovens Pesqui., 2014, 4(3), 38-51.
[34]
Onwuchuruba, C.N.; Towers, C.V.; Howard, B.C.; Hennessy, M.D.; Wolfe, L.; Brown, M.S. Transplacental passage of vancomycin from mother to neonate. Am. J. Obstet. Gynecol., 2014, 210(4), 352.e1-352.e4.
[35]
Ringer, S.A. Acute renal failure in the neonate. Neoreviews, 2010, 11(5), e243-e251.
[36]
Rocha, M.J.S.P. Caracterização do perfil cinético de gentamicina e vancomicina em recém-nascidos prematuros., Doctor Thesis, Universidade de Coimbra: Coimbra. 2006.
[37]
Macdougall, C.; Chambers, H.F. Inibidores da síntese de proteínas
e agentes antibacterianos diversos. In: Goodman & Gilman’s as
bases farmacológicas da terapêutica, Laurence L. Brunton, Ed.;
McGraw-Hill Interamericana do Brasil: Rio de Janeiro. 2012, 12
ed. pp. 1521-1547.
[38]
Ye, Z-K.; Tang, H-L.; Zhai, S-D. Benefits of therapeutic drug monitoring of vancomycin: A systematic review and meta-analysis. PLoS One, 2013, 8(10), e77169.
[39]
Levine, D.P. Vancomycin: A History. Clin. Infect. Dis., 2006, 42(Suppl. 1), S5-S12.
[40]
Bond, C.A.; Raehl, C.L. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am. J. Health Syst. Pharm., 2005, 62(15), 1596-1605.
36
6